Drug Approval | March 12, 2026
FDA nod to first treatment for rare genetic brain disorder
The approval comes after a systematic review of published literature
The approval comes after a systematic review of published literature
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Subscribe To Our Newsletter & Stay Updated
